(Q43632861)

25 November 2017

Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine (English)

1 reference

25 November 2017

0 references

1 reference

Farlow MR

1

1 reference

25 November 2017

1 January 2001

1 reference

25 November 2017

Clinical Therapeutics

1 reference

25 November 2017

23 Suppl A

1 reference

25 November 2017

A13-24

1 reference

Estimated prevalence of Alzheimer's disease in the United States

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

1 reference

7 January 2021

Galantamine: a review of its use in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

The cholinergic hypothesis of Alzheimer's disease: a review of progress

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

Nicotinic acetylcholine involvement in cognitive function in animals

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

Neuronal nicotinic receptors in synaptic functions in humans and rats: physiological and clinical relevance.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

Treatment of REM sleep behavior disorder with donepezil: a report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980164-8

7 January 2021

10.1016/S0149-2918(01)80164-8

Identifiers

DOI

1 reference

25 November 2017

1 reference

PubMed ID

11396867